BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA

Martina Bogeljić Patekar¹, Vibor Milunović¹, Karla Mišura Jakobac¹, Dražen Perica³, Inga Mandac Rogulj¹, Marin Kursar¹, Ana Planinc-Peraica¹,³ and Slobodanka Ostojić Kolonić¹,³

¹Division of Hematology, Merkur University Hospital, Zagreb, Croatia; ²Lombardi Comprehensive Cancer Centre, Georgetown University, Washington, D.C., United States of America; ³School of Medicine, University of Zagreb, Zagreb, Croatia

SUMMARY – The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for rituximab-resistant indolent NHL and CLL in patients not fit for conventional chemotherapy. Recent studies have shown superiority of bendamustine combination with rituximab (B-R) in first line treatment of indolent NHLs and mantle cell lymphoma, suggesting a shift of the standard of care in this setting. B-R regimen has also shown efficacy in relapsed setting suggesting the possible treatment option for patients failing conventional chemotherapy. In rituximab-resistant NHL, the recent GADOLIN study exploring the addition of obinutuzumab to bendamustine has yielded impressive result changing the standard of care in this hard-to-treat population. Concerning CLL, despite inferiority to the standard of care in young fit patients, as defined in CLL10 study, B-R has yielded a more beneficial toxicity profile and its use in first line treatment should be decided individually. In relapsed setting, the addition of ibrutinib to B-R has shown superior results compared to B-R alone, possibly changing the paradigm of treatment of relapsed CLL. In conclusion, bendamustine as a single agent or in combinations has shown activity with acceptable toxic profile in the treatment of patients with indolent NHLs or CLL without del(17p) mutation.

Key words: Bendamustine hydrochloride; Alkylating agents; Lymphoma, non-Hodgkin; Rituximab; Leukemia, lymphocytic, chronic; B-cell; Obinutuzumab

Introduction

Non-Hodgkin lymphomas (NHL) represent the most common malignancy in hematologic oncology. According to the US SEER program, its incidence is 19.5 cases per 100 000 men and women, with 70.7% of patients surviving for 5 years¹. Chronic lymphocytic leukemia (CLL) is the most common leukemia of elderly with the incidence of 4.6 cases per 100 000 men and women, with 82.6% of patients surviving for 5 years according to the SEER program². In Croatia, the incidence of NHL is estimated to 6.96 per 100 000 men and 5.57 per 100 000 women³. The incidence of CLL is 2.59 per 100 000 men and 1.2 per 100 000 women. It is important to note that NHLs are heterogeneous disorders varying from aggressive type such as diffuse large B cell lymphoma (DLBCL) to indolent one such as follicular lymphoma (FL). In a recent international classification study on NHL in south-eastern Europe, the most common type of NHL was DLBCL (37%), followed by FL (20.2%)⁴. In this study, CLL was included as NHL with a prevalence of 12.5%.

Correspondence to: Martina Bogeljić Patekar, MD, Division of Hematology, Merkur University Hospital, Zajčeva ulica 19, HR-10000 Zagreb, Croatia
E-mail: bogeljic.patekar@gmail.com
Received June 20, 2016, accepted February 16, 2017
Bendamustine belongs to a group of alkylating agents, however, it has a distinct pharmacodynamic profile. In vitro, it phosphorylates tumor suppressor p53 leading to apoptosis. Second mechanism is DNA repair by upregulation of EXO1 gene leading to a base excision repair pathway response. Third mechanism is inducing mitotic catastrophe causing downregulation of several genes involved in mitotic checkpoints leading to multinucleation or micronucleation and chromatin condensation (all events as hallmarks of mitotic catastrophe). It is important to note that the mechanism of bendamustine action still is not known and additional studies are needed to define the precise pharmacodynamic profile. Bendamustine also has a favorable pharmacokinetic profile regardless of sex, age and race. Concerning hepatic dysfunction, no difference in pharmacokinetics has been found between normal function and mild hepatic impairment. Data on severe and moderate hepatic impairment are scarce, so caution is warranted when using bendamustine in this patient subpopulation. Concerning renal impairment, difference in the safety profile is not of clinical concern. Patients with renal impairment defined as creatinine clearance <40 mL/min had only two higher adverse events, i.e. blood urea nitrogen and thrombocytopenia. These data are further supported by excellent tolerability in multiple myeloma patients with renal dysfunction treated by bendamustine. Historically, bendamustine was first synthesized and used in Eastern Germany during the Soviet era, but with the fall of the Berlin Wall, further research made it available worldwide.

The main aim of this review is to assess data on the activity of bendamustine alone or in combinations in NHLs and CLL.

Bendamustine as First Line Therapy in NHL: the End of CHOP-R Era?

Anthracycline-based regimen in combination with rituximab, so called CHOP-R regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) has been the mainstay of treatment in CD20 positive NHLs. First frontline study examining bendamustine in combination with rituximab (B-R) versus CHOP-R regimen in indolent NHLs was performed by the Sti1 group for indolent lymphomas. It was a phase III non-inferiority randomized clinical trial which included 549 patients with high tumor burden indolent NHLs and mantle cell lymphoma (MCL) randomized at a 1:1 ratio to receive either CHOP-R or B-R regimen for up to 6 cycles (dose of bendamustine 90 mg/m² on days 1 and 2). Despite the non-inferiority design, improvement of progression-free survival (PFS) favored B-R with median PFS of 69.5 months as compared with only 31.2 months for CHOP-R. Additional analysis was based on histology. In FL, PFS in the B-R arm was not reached as compared with 40.9 months in the CHOP-R arm. Interestingly, B-R outperformed CHOP-R in MCL (35.4 vs. 22.1 months), which is important since the addition of rituximab to CHOP regimen never showed advantages in terms of long-term outcomes in these patients. However, overall survival (OS) did not differ between the groups, with median not being reached. One reason may have been short follow-up and small number of events in both arms. Another and more probable reason lies in the cross-over design of the study, i.e. the patients that progressed during or after CHOP-R regimen were salvaged by B-R (N=116). B-R was also characterized by a distinct toxicity profile. Concerning hematologic adverse events, lower rates of leukopenia and neutropenia were observed with consequent lower rates of infectious episodes (37% vs. 50%). Concerning non-hematologic events, virtually no alopecia was observed in B-R group with lower rates of paresthesia, which are vincristine-induced in CHOP-R protocol, and stomatitis. On the other hand, skin erythema and skin allergic reaction were more pronounced in B-R group (16% and 15%, respectively).

Another large study in this setting was the BRIGHT non-inferiority study on 447 patients comparing B-R (dose of bendamustine 90 mg/m² on days 1 and 2) to CHOP-R or CVP-R (rituximab, cyclophosphamide, vincristine and prednisone) regimens in indolent NHLs or MCL, up to 6 cycles with additional 2 cycles permitted per investigator discretion. Primary objective was complete response (CR) as measured by the "revised response criteria for malignant lymphoma". CR response was achieved in 31%
of B-R group compared to 25% in CHOP-R/CVP-R group, although the difference was not statistically significant. Overall response rate (ORR) was similar between the groups (97% and 91%, respectively). In further analysis, all variables favored B-R regimen with MCL being once again the most prominent one. Concerning safety profile, B-R regimen produced fewer hematologic adverse events, primarily, leukopenia, neutropenia and lymphocytopenia. The rates of infections were similar between the groups. Once again, B-R did not cause alopecia. Drug hypersensitivity was noted in B-R group, mainly in the form of skin reactions, but this toxicity was manageable. At the time of writing this review, no data on PFS and OS in the BRIGHT study were available. Interestingly, B-R regimen was better tolerated than CHOP-R or CVP-R as measured by quality of life (QoL) questionnaires. Patients reported improved outcomes on many scales such as cognitive, physical, social and emotional functioning, indicating major QoL improvement in patients receiving B-R.

In conclusion, B-R has demonstrated equal or better effect to the standard of care, improvement in outcomes in terms of PFS, major improvement in MCL histology, distinct but favorable toxicity profile, and better tolerability. This has led some authors to declare the end of the CHOP-R era in indolent NHLs.

However, none of the pivotal studies had maintenance strategy with rituximab in protocol. Maintenance with rituximab every 2 months in case of CR or partial remission (PR) has become the standard of care in Europe based on PRIMA results showing improved 3-year PFS of 74.9% in maintenance group compared with 57.6% in observation group. To address this question, the MAINTAIN trial was designed. This was a phase III trial with three arms comparing rituximab maintenance for 2 years, 4 years, and observation after B-R induction. This approach showed feasibility and no safety signal was noted in preliminary analysis. However, initial results in subset analysis of 120 MCL patients were disappointing. After median follow-up of 54.2 months, two groups did not differ in PFS (not reached vs. 54.7 months) or OS. The authors conclude that the follow-up was too short to present definitive results. Until then, maintenance strategy following B-R in indolent NHLs or MCL is purely experimental.

Furthermore, in the era of B cell receptor (BCR) signaling, B-R is attractive backbone regimen for combinations with this inhibitor. Yet, we have learnt a lesson in a hard way with idelalisib, a PI3Kδ inhibitor approved for refractory indolent NHLs. In first line setting, it was combined with B-R in the treatment of indolent NHLs or CLL. Despite excellent response rates, the studies were terminated due to unexpected toxicity affecting survival curve (cytomegalovirus reactivation, Pneumocystis jirovecii infections, colitis, trans-

Table 1. Results of non-inferiority studies comparing B-R regimen and conventional chemotherapy in indolent NHLs or MCL

| Author | Phase | B dose (mg/m²) | Arm | N | Primary outcome | Secondary outcome |
|--------|-------|----------------|-----|---|----------------|------------------|
| Rummel¹⁵ | III | 90 | B-R vs. CHOP-R | 549 | PFS 69.5 months vs. 31.2 months | ORR 93% vs. 91%* |
| Flinn¹⁷ | III | 90 | B-R vs. CHOP-R/CVP-R | 447 | CR 31% vs. 25%* | ORR 97% vs. 91%* |

*nonsignificant; NHL = non-Hodgkin lymphoma; MCL = mantle cell lymphoma; B-R = bendamustine-rituximab; B=bendamustine; PFS = progression-free survival; CR = complete remission; ORR = overall response rate
aminitis, and pneumonitis)\textsuperscript{32}. This should serve as a warning that combination therapy with BCR inhibitors should not be taken lightly.

Concerning DLBCL, to our knowledge, there is no published study evaluating B-R in first line setting, although a phase II trial is ongoing evaluating feasibility of this approach in elderly patients with previously untreated DLBCL\textsuperscript{33}. 

Bendamustine in Relapsed Setting

Indolent NHLs or MCL

There is only one randomized phase III trial evaluating B-R (dose 90 mg/m\textsuperscript{2}) \textit{versus} fludarabine based regimen (FR, dose of fludarabine 25 mg/m\textsuperscript{2} on day 1-3)\textsuperscript{34}. The study included 219 patients with indolent NHLs or MCL, randomized at a 1:1 ratio. The primary objective was PFS, favoring B-R regimen with 34.2 months compared to only 11.7 months in F-R group. The authors demonstrated better OS for B-R group (109.7 months and 49.1 months, respectively). B-R and F-R had a similar toxicity profile, myelosuppression and infections. The importance of this trial is that B-R was highly active in relapsed setting and could be used as a retreatment strategy in relapsed or refractory indolent NHLs and MCL\textsuperscript{25}. Other single arm trials evaluating B-R regimen in this setting are summarized in Table 2.

In conclusion, B-R regimen is a viable option in the treatment of patients with relapsed indolent NHLs and MCL not fit for stem cell transplant with high ORR rates, adequate duration of response and manageable toxicity.

There are multiple trials under way exploring addition of other agents such as lenalidomide, bortezomib, duvelisib (dual PI3K\(\delta\) and \(\gamma\) inhibitor) or temsirolimus to enhance the activity of B-R regimen itself\textsuperscript{39-42}.

Bendamustine in rituximab-refractory indolent NHL

Eventually, a significant proportion of patients will develop refractoriness to rituximab defined as stable disease (SD) or progressive disease (PD) after rituximab therapy or progression during the first 6 months after completion of therapy. Traditionally, these patients had poor outcomes and represented clinical challenge for treatment strategy.

One study explored bendamustine (dose 120 mg/m\textsuperscript{2}) in 76 patients with rituximab-refractory indolent or transformed NHL\textsuperscript{43}. The proportion of patients with transformed NHL was 20%. ORR for the whole group was 77% with 34% CR. ORR for indolent NHLs was 82% with 17 CR and median PFS of 8.25 months. However, duration of response in transformed NHLs was much shorter with PFS being only 4.18 months.

The pivotal study in this area was conducted by Kahl \textit{et al.} including 100 patients with rituximab-resistant NHLs\textsuperscript{44}. The median number of previous therapies was 2 with 36% of patients being refractory to previous therapy. Bendamustine was administered as a single agent at a dose of 120 mg/m\textsuperscript{2} on days 1 and 2 for up to 8 cycles. ORR for the whole group was 77%. Interestingly, bendamustine produced high-level response in chemorefractory group (ORR=64%) and alkylator-refractory group (ORR=60%) due to its non-cross resistant properties. However, duration of response was rather short being 9.2 months with median PFS of 9.3 months. This study led to approval of bendamustine under current designation in the USA and Croatia\textsuperscript{21,23}. Recently, great breakthrough was achieved in this setting with results of the GADOLIN study\textsuperscript{45}. This phase III trial explored whether the addition of obinutuzumab, a type II antiCD20 antibody, to bendamustine (90 mg/m\textsuperscript{2} on day 1 or 2) followed by maintenance was superior to bendamustine alone. It should be noted that the design of the study was unbalanced since patients in the comparator arm received bendamustine in a dose of 120 mg/m\textsuperscript{2} on day 1 or 2. A
total of 396 patients were randomized at the 1:1 ratio. Despite similar ORR between the groups (69.1% vs. 63%), PFS was significantly different and not reached in G-B group compared to 14 months in B group after median follow-up of 20 months. This efficacy of G-B regimen to produce lasting responses may be attributed to eradication of minimal residual disease (MRD)\(^46\). In subanalysis of 93 patients, eradication of t(14;18), a pathognomonic event in FL, was associated with improved outcome, with 82% of patients achieving negativity in G-B group compared to 43% of patients in B group. PFS in patients that achieved MRD negativity in G-B group was not reached as compared with 7.6 months in B group. Outcomes of MRD positive patients were poor regardless of the treatment arm, with PFS of 5.4 months in G-B group and 3 months in B group. The GADOLIN trial subsequently led to approval of obinutuzumab in combination with bendamustine for rituximab-refractory indolent NHLs\(^47\). It is important to note that this drug has not yet been approved in the EU for this indication\(^48\). The studies are summarized in Table 3. Owing to excellent outcomes in rituximab-resistant indolent NHLs, the G-B regimen might be included in the standard of care of this hard-to-treat population.

| Author     | Phase | B dose (mg/m\(^2\)) | N  | Primary outcome | Secondary outcome |
|------------|-------|---------------------|----|-----------------|------------------|
| Friedberg  | II    | 120                 | 76 | ORR 82%         | PFS 8.25 months  |
| Kahl       | II    | 120                 | 100| ORR 77%         | PFS 9.3 months   |
| Sehn       | III   | 120 (G-B) / 90 (B)  | 396| ORR 69.1 vs. 63%| PFS not reached vs. 14 months |

NHL = non-Hodgkin lymphoma; G-B = obinutuzumab-bendamustine; B = bendamustine; ORR = overall response rate; PFS = progression-free survival

Is there a role for bendamustine in relapsed or refractory DLBCL?

In young fit patients with relapsed or refractory DLBCL, high dose chemotherapy combined with rituximab followed by ASCT represents a standard of care\(^49,50\). However, a significant subset of patients are not candidates for high dose chemotherapy and the standard of care remains elusive in this population\(^51\). Owing to its properties, mainly as alkylator non-cross resistant and favorable toxicity profile, bendamustine may be the drug of choice in this setting. Several phase II trials evaluated the activity of B-R regimen in relapsed or refractory DLBCL. The largest trial included 69 patients receiving B-R (dose of bendamustine 120 mg/m\(^2\) on day 1 or 2)\(^52\). The ORR was high (62.7%) with 37.3% of CR, but the response did not translate in PFS, which was only 6.7 months. All published studies on B-R regimen in relapsed or refractory DLBCL are summarized in Table 4.

Table 4. Studies on B-R regimen in relapsed or refractory DLBCL

| Author     | Phase | B dose (mg/m\(^2\)) | N  | Primary outcome | Secondary outcome |
|------------|-------|---------------------|----|-----------------|------------------|
| Ohmach\(^52\) | II    | 120                 | 69 | ORR 62.7%       | PFS 6.7 months   |
| Vacirca\(^53\) | II    | 120                 | 59 | ORR 45.8%       | PFS 3.6 months   |
| Merchionne\(^54\) | Retrospective | 90/120 | 28 | ORR 50%         | PFS 8 months     |

DLBCL = diffuse large B cell lymphoma; ORR = overall response rate; PFS = progression-free survival

In conclusion, there are limited data on B-R activity in relapsed or refractory DLBCL. B-R regimen results in relatively high ORR, but long term outcomes are poor. This regimen should be offered to a limited number of patients in whom more aggressive therapy is not a valid option due to comorbidities. Furthermore, this regimen based on data from phase II trials should not be pursued further in the treatment of DLBCL, especially in the era of BCR inhibitors\(^55\).

Bendamustine in CLL

Bendamustine in the treatment of CLL; first line setting

Due to demonstration of in vitro efficacy of bendamustine in CLL cell lines, it has become an attractive agent in the treatment of CLL\(^56\). The pivotal study in this area is comparison of bendamustine (100 mg/m\(^2\) on days 1 and 2) to chlorambucil (0.8 mg/kg on days 1 and 15) in 319 patients for up to 6 cycles\(^57\). Primary
objective was ORR achieved in 68% in B arm compared to 31% in Chl arm. Higher rates of CR were noted in patients treated with B (31% and 2%, respectively). This advantage translated in the improvement of PFS with median PFS of 21.6 months in B arm compared to only 8.3 months in Chl arm. Concerning safety profile, B arm was associated with more toxicity, mainly skin allergic reaction, but hematologic toxicities were also more pronounced, resulting in a higher frequency of severe infections (8% vs. 3%). Updated results with a median follow-up of 54 months did not show OS benefit when stratifying patients according to age or CLL stage. However, in the analysis according to objective response, median OS was not reached in B group compared to 68.3 months in Chl group. These results led to approval of bendamustine use in CLL in first line setting in patients who are not able to tolerate the FCR (fludarabine, cyclophosphamide, rituximab) regimen.

Based on in vitro studies and activity in indolent NHLs, the question arises if bendamustine could be the backbone chemotherapy in combination with rituximab. The preliminary data come from a phase II trial on 117 patients with untreated CLL. B-R (dose 90 mg/m² on days 1 and 2) resulted in impressive ORR of 88% with 23.1% of CR. The median event-free survival (EFS) was 33.9 months with the majority of patients being alive at the end of follow-up. However, we must note that ORR (37.5%) was lower in patients harboring ominous del(17p), indicating that B-R is not an appropriate regimen for this subpopulation. There is an ongoing phase III MaBLe study comparing B-R to R-Chl, for which definitive results were not available at the time of writing this review.

Yet, despite the fact that bendamustine was compared to chlorambucil, a ‘sick young puppy’ as the world renowned expert Bruce Cheson would call it, comparison with FCR, the standard of care in young, fit patients without del(17p) was needed. To address this question, the CLL 10 study was designed including 561 young fit patients without del(17p) as non-inferiority study comparing B-R (dose 90 mg/m² on days 1 and 2) to FCR for up to 6 cycles. Primary endpoint was PFS of 41.7 months in B-R compared to 55.2 months in FCR group, indicating that B-R was inferior in this setting. ORR was similar between the groups (95% vs. 96%), with a higher rate of CR in FCR group (31% vs. 96%). However, the treatment with FCR comes with multiple adverse events, mainly hematologic toxicities, leading to a greater rate of infections (77% vs. 65%). Furthermore, FCR causes prolonged myelosuppression with the possibility of late infections after completion of therapy. Another safety signal in FCR is the occurrence of secondary malignancies with a 2.38 risk to develop therapy-related acute myelogenous leukemia or myelodysplastic syndrome (5.1%) or Richter transformation to DLBCL (9%). Both entities are associated with dismal outcomes.

In our opinion, despite being inferior to FCR, B-R regimen should be introduced in the real-world clinical setting. The basis of treatment should be made upon specific goals and patient comorbidities, i.e. the choice of B-R regimen should be made individually in first line setting of CLL.

Recently, feasibility of obinutuzumab in combination with FC (fludarabine, cyclophosphamide) or bendamustine in a dose of 90 mg/m² (G-B) was explored in the Galton phase IB study. The number of patients in G-B group was 20 with impressive ORR of 90% with 20% CR and 25% CR with incomplete marrow recovery. After median follow-up of 23.5 months, none of the patients progressed or died. The safety profile was manageable with most prominent adverse effect being infusion related reaction in 90% of patients, occurring primarily at first G-B cycle. Based on the efficacy of this regimen, a phase II trial is currently ongoing evaluating G-B in previously untreated CLL.

Bendamustine was also investigated in combination with ofatumumab, human antiCD20 antibody leading to cell lysis and antibody-dependent cell-mediated cytotoxicity. This drug was firstly approved in the EU for the treatment of patients refractory to fludarabine and alemtuzumab. In a study on 40 previously untreated patients unsuitable for FCR chemotherapy, the ORR was 95% with 43% CR. Toxicity profile was tolerable with infusion reactions being the most common adverse event. The pivotal study in this area is the OMB11 5991 study on 44 patients not fit enough for FCR regimen. ORR was 95% with 43% CR. It is important to note that more than half of the patients achieved MRD negativity, i.e. B-R can achieve molecular response. This led to approval of this regimen in patients who are not fit enough to tolerate FCR protocol. However, we must note that due to
the clear superiority of rituximab and its worldwide use, ofatumumab is rarely used in clinical practice and the real impact of these regimens in everyday use remains unknown. The results of studies described above are summarized in Table 5.

**Table 5. Bendamustine in first line setting of CLL**

| Author   | Phase | B dose (mg/m²) | Arm   | N  | Primary outcome       | Secondary outcome                          |
|----------|-------|----------------|-------|----|-----------------------|--------------------------------------------|
| Knauf 57 | III   | 100            | B vs. Chl | 319 | ORR 68% vs. 31%       | Median PFS 21.6 vs. 8.3 months             |
| Fischer 59 | II    | 90             | B-R   | 117 | ORR 88%               | Median EFS 33.9 months                     |
| Eichhorst 63 | III   | 90             | B-R vs. FCR | 561 | Median PFS 41.7 vs. 55.2 months | ORR 95% vs. 96%                           |
| Brown 66 | I     | 90             | G-B   | 20  | ORR 90%               | NA                                         |
| Offner 70 | II    | 90             | O-B   | 40  | ORR 95%               | NA                                         |
| OMB11 591169 | II    | 90             | O-B   | 47  | ORR 95%               | MRD negativity 56%                         |

CLL = chronic lymphocytic leukemia; B = bendamustine; Chl = chlorambucil; B-R = bendamustine-rituximab; FCR = fludarabine, cyclophosphamide, rituximab; G-B = obinutuzumab-bendamustine; O-B = ofatumumab-bendamustine; ORR = overall response rate; PFS = progression-free survival; EFS = event-free survival; NA = not applicable; MRD = minimal residual disease

**Table 6. Bendamustine in relapsed or refractory CLL**

| Author          | Phase | B dose (mg/m²) | Arm          | N  | Primary outcome | Secondary outcome                      |
|-----------------|-------|----------------|--------------|----|----------------|----------------------------------------|
| Lissitchkov 71  | I     | 100            | B-R          | 15 | ORR 60%        | NA                                     |
| Fischer 72      | II    | 70             | B-R          | 78 | ORR 50%        | EFS 14.7 months                        |
| Cortelezzi 73   | II    | 70             | B-O          | 47 | ORR 72.3%      | OS 33.9 months                         |
| Chanan-Khan 74  | III   | 70             | B-R+ibrutinib| 578| Median PFS not reached vs. 13.3 months | 2-year OS 83.6% 2-year PFS 49.6%         |

CLL = chronic lymphocytic leukemia; B = bendamustine; B-R = bendamustine-rituximab; B-O = bendamustine-ofatumumab; ORR = overall response rate; PFS = progression-free survival; OS = overall survival; EFS = event-free survival; NA = not applicable

A larger phase II study included 78 patients treated with B-R regimen (dose 70 mg/m² on day 1 or 2) 72. ORR was 50% with 9% CR and 47.4% PR. In subgroup analysis, patients with del(17p) had the worst outcome with ORR being only 7.1%. It is important to note that ORR was high in fludarabine-resistant patients (45.5%). The median EFS was 14.7 months after 24-month follow-up. The median OS was 33.9 months. The regimen was associated with more toxicity than in the first line setting. The adverse events of concern were severe infections that occurred in 12.8% of patients, but this toxicity profile is expected in heavily pretreated patients.

In the Italian phase II trial, 47 patients were enrolled receiving bendamustine (dose 70 mg/m² on day 1 or 2) in combination with ofatumumab for up to 6 cycles 73. B-O regimen resulted in ORR of 72.3% with 17% CR. It also yielded somewhat better ORR of 30%
in del(17p) subgroup. After median follow-up of 24.2 months, 2-year OS and PFS rates were 83.6% and 49.6%, respectively.

However, most interesting is the addition of ibrutinib, an oral Bruton kinase inhibitor to B-R regimen in the phase III Helios study74; 578 patients were assigned to receive either placebo or ibrutinib in addition to B-R (dose 70 mg/m² on day 1 or 2) for up to 6 cycles. Ibrutinib was administered until disease progression or unacceptable toxicity. The main objective was PFS, which was not reached in ibrutinib group as compared with 13.3 months in placebo group. ORR was higher in ibrutinib group (83% vs. 68%). In post hoc analysis, all variables favored ibrutinib treatment. The addition of ibrutinib did not result in additional safety signals. One of the possible pitfalls of the study was not including patients with del(17p) for which ibrutinib was assigned to receive either placebo or ibrutinib in addition to B-R (dose 70 mg/m² on day 1 or 2) for up to 6 cycles. Ibrutinib was administered until disease progression or unacceptable toxicity. The main objective was PFS, which was not reached in ibrutinib group as compared with 13.3 months in placebo group. ORR was higher in ibrutinib group (83% vs. 68%). In post hoc analysis, all variables favored ibrutinib treatment. The addition of ibrutinib did not result in additional safety signals. One of the possible pitfalls of the study was not including patients with del(17p) for which ibrutinib has become the standard of care75-77.

In conclusion, B-R regimen seems like a reasonable option in patients failing FCR. Concerning the addition of ibrutinib to B-R, we must wait for reaction of regulatory agencies, i.e. whether ibrutinib will be registered in combination with B-R for the treatment of relapsed or refractory CLL. All the studies are summarized in Table 6.

Conclusion

As shown above, bendamustine alone or in combinations with other agents has shown impressive activity in indolent NHLs, MCL and CLL without del(17p). We must highlight certain combinations which may be a standard of care in various settings of these diseases, as follows:

1. B-R for first line setting in indolent NHLs or MCL,
2. G-B for rituximab-resistant indolent NHLs,
3. B-R for selected patients with CLL without del(17p), and
4. B-R in combination with ibrutinib for relapsed CLL without del(17p).

However, we are in the era of BCR pathway inhibitors, so the question arises whether bendamustine is still relevant while pursuing the ‘chemo-free’ era. However, these agents have shown unexpected toxicities, especially in first line setting, leading to early termination of multiple trials and causing ‘speed bumps’ on our way to ‘chemo-free’ era78. Until we learn how to combine these inhibitors with acceptable toxicity profile, bendamustine will remain relevant in every day hematologic practice.

References

1. Surveillance, Epidemiology and End Results Program. SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. Accessed online 5/25/2016 from URL: http://seer.cancer.gov/statfacts/html/nhl.html
2. Surveillance, Epidemiology and End Results Program. EER Stat Fact Sheets: Chronic Lymphocytic Leukemia (CLL). Accessed online 5/25/2016 from URL:http://seer.cancer.gov/statfacts/html/clyl.html
3. Novak I, Jakšić O, Kuliš T, Batinjan K, Znaor A. Incidence and mortality trends of leukemia and lymphoma in Croatia, 1988-2009. Croat Med J. 2012;53:115-23.
4. Dotlic S, Perry AM, Petrusevska G, Fetica B, Diebold J, MacLennan KA, et al. Classification of non-Hodgkin lymphoma in south-eastern Europe: review of 632 cases from the International Non-Hodgkin Lymphoma Classification project. Br J Haematol. 2015;171:366-72. https://doi.org/10.1111/bjh.13586
5. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbelli J, Elliott G, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14:309-17. https://doi.org/10.1158/1078-0432.CCR-07-1061
6. Darwish M, Bond M, Hellriegel E, Robertson P Jr, Chovan JP. Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015;75:1143-54. https://doi.org/10.1007/s00280-015-2727-6
7. Nordstrom BL, Knopp KB, Teltsch DY, Engle R, Beigy H, Sterchele JA. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis. Leuk Lymphoma. 2014;55:1266-73. https://doi.org/10.3109/10428194.2013.836600
8. Pönisch W, Moll B, Bourgeois M, Meurger C, Schliebe T, Heyn S, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol. 2013;139:1937-46. https://doi.org/10.1007/s00432-013-1513-2
9. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S, et al. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol. 2011;155:632-4. https://doi.org/10.1111/j.1365-2141.2011.08754.x
10. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-42. https://doi.org/10.1056/NEJMoa011795
Bendamustine in lymphoproliferative disorders

11. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schnirns R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-32. https://doi.org/10.1182/blood-2005-01-0016

12. Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLLO5 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31:1506-13. https://doi.org/10.1200/JCO.2012.45.0866

13. Chow KU, Boehler S, Geduldig K, Krapohl A, Hoelzer D, Mittou PS, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica. 2001;86:485-93.

14. Rummel MJ, Chow KU, Hoelzer D, Mittou PS, Weidmann E. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol. 2002;29:12-4.

15. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203-10. https://doi.org/10.1016/S0140-6736(12)61763-2

16. Lenz G, Dreyling M, Hoster E, Wörmann B, Dühsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984-92. https://doi.org/10.1200/JCO.2005.08.133

17. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944-52. https://doi.org/10.1182/blood-2013-11-531327

18. Cheson BD, Pfister R, Jusweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86. https://doi.org/10.1200/JCO.2006.09.2403

19. Burke JM, van der Jagt RH, Kahl BS, Wood P, Hawkins TE, MacDonald D, et al. Differences in quality of life between bendamustine-rituximab and R-CHOP/R-CVP in patients with previously untreated advanced indolent non-Hodgkin lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2016;16:182-90. https://doi.org/10.1016/j.clml.2016.01.001

20. Jacobson CA, Freedman AS. First-line treatment of indolent lymphoma: axing CHOP? Lancet. 2013;381:9873. https://doi.org/10.1016/S0140-6736(12)61965-5

21. Food and Drug Administration. TREANDA® (bendamustine hydrochloride) for Injection, for intravenous infusion. Accessed online 5/26/2016 from URL:http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022303lbl.pdf

22. European Medicines Agency. Levact. Accessed online 5/26/2016 from URL:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Levact/human_referall_000199.jsp&mid=WC0b01ac0580024e9a

23. Croatian Health Insurance Fund. [Basic list of medicines] Accessed online 5/26/2016 from URL:http://www.hzoz.hr/zdравственi-sustav-rh/trazilica-za-lijekove-s-vazecih-lista/

24. Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii76-82. https://doi.org/10.1093/annonc/mdu200

25. Zelezny AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Non-Hodgkin’s lymphomas, version 2.2014. J Natl Compr Canc Netw. 2014;12:916-46.

26. Auer I, Gasparov S, Krlik M, Balenovic A, HuÌÁ D, Søntek F, Dületic-Nacinovic A, et al. [Lymphoma diagnosis and treatment – second Croatian consensus]. Lijec Vjesn. 2013;135:63-76. (in Croatian)

27. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42-51. https://doi.org/10.1016/S0140-6736(10)62175-7

28. Barth J. Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas (MAINTAIN). In Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine. 2015—[cited 29/5/2016]

29. Rummel MJ, Viardot A, Greil R, et al. Bendamustine plus rituximab followed by rituximab maintenance for patients with untreated advanced follicular lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier:NCT00877214) Blood 2014;124;3052

30. Rummel MJ, Knauf W, Goerner M, et al. Two year rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34 Suppl: Abstract 7503.

31. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008-18. https://doi.org/10.1056/NEJMoa1314583

32. Food and Drug Administration. FDA Alerts Healthcare Professionals about Clinical Trials with Zydelig (idelalisib) in
Combination with other Cancer Medicines. Accessed online 5/30/2016 from URL:http://www.fda.gov/Drugs/DrugSafety/ucm490618.htm
33. UNC Lineberger Comprehensive Cancer Center. Bendamustine + Rituximab in older patients with previously untreated diffuse large B-cell lymphoma. In Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine. 2016.-[cited 30/5/2016]
34. Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17:57-66. https://doi.org/10.1016/S1470-2045(15)00447-7
35. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-9. https://doi.org/10.1200/JCO.2005.08.100
36. Robinson KS, Williams ME, van de Jagt RH, Cohen P, Herst JA, Tulpule A, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4473-9. https://doi.org/10.1200/JCO.2008.17.0001
37. Weide R, Hess G, Köppler H, Heymanns J, Thomalla J, Aldaoud A, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma. 2007;48:1299-306. https://doi.org/10.1080/10428190701361828
38. Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442-9. https://doi.org/10.1200/JCO.2012.45.9842
39. Hess G. Tensirilimus, Bendamustine and rituximab for relapsed follicular lymphoma or mantle cell lymphoma (BERT) In Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine. 2015.-[cited 30/5/2016]
40. Millennium Pharmaceuticals, Inc. A Phase II Study of VELCADE (Bortezomib) in combination with bendamustine and rituximab in subjects with relapsed or refractory follicular lymphoma (VERTICAL) In Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine. 2012.-[cited 30/5/2016]
41. Alliance for Clinical Trials in Oncology. Rituximab, bendamustine hydrochloride, and lenalidomide in treating patients with refractory or relapsed indolent non-Hodgkin lymphoma In Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine. 2015.-[cited 30/5/2016]
42. Infinity Pharmaceuticals, Inc. A study of duvelisib in combination with rituximab and bendamustine vs placebo in combination with rituximab and bendamustine in subjects with previously-treated indolent non-Hodgkin lymphoma (BRAVURA). In Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine. 2016.-[cited 30/5/2016]
43. Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casse AS, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204-10. https://doi.org/10.1200/JCO.2007.12.5070
44. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116:106-14. https://doi.org/10.1002/cncr.24714
45. Sehn L, Chua N, Mayer J, Dueck G, Triený M, Boubadhallah K, et al. GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2015;33:LBA8502.
46. Pott C, Belada D, Danesi N, et al. Analysis of minimal residual disease in follicular lymphoma patients in GADOLIN, a phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed/refractory indolent non-Hodgkin lymphoma. Blood 2015;126:3978.
47. Food and Drug Administration. Obinutuzumab. Accessed online 5/30/2015 from URL:http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm488013.htm
48. European Medicines Agency. Gazyva® Product information. Accessed online 5/30/2015 from URL:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002799/human_med_001780.jsp&mid=CVID=WC0b01ac058001dd4
49. Philip T, Guglielmi C, Hagenbeck A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;335:1540-5.
lapsed or refractory diffuse large B cell lymphoma. Ann Hematol. 2014;93:403-9. https://doi.org/10.1007/s00277-013-1879-x

54. Merchionne F, Quintana G, Gaudio F, Minoia C, Specchia G, Guarini A, et al. Bendamustine plus rituximab for relapsed or refractory diffuse large B-cell lymphoma: a retrospective analysis. Leuk Res. 2014;38:1446-50. https://doi.org/10.1016/j.leukres.2014.10.001

55. Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea. Evaluation of ibrutinib in patients with refractory/refractory non-GCB diffuse large B-cell lymphoma non candidates to Autologous Stem Cell Transplantation (ASCT) In Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine. 2015-[cited 31/5/2016]

56. Schwänen C, Hecker T, Hübinger G, Wölfl e M, Rittgen W, Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Bergmann L, et al. Ofatumumab in combination therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015;56:1643-50. https://doi.org/10.3109/10428194.2014.97203

61. Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928-42. https://doi.org/10.1016/S1470-2045(16)30051-1

64. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, et al. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukaemia: analysis of persistent and new-onset cytopenia. Cancer. 2013;119:3805-11. https://doi.org/10.1002/cncr.28318

65. Benjami ni O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, Wang X, et al. Second cancers in patients with chronic lymphocytic leukaemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015;56:1643-50. https://doi.org/10.3109/10428194.2014.97203

66. Brown JR, O’Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, et al. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015;125:2779-85.
74. Chanan-Khan A1 Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200-11. https://doi.org/10.1016/S1470-2045(15)00465-9

75. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425-37. https://doi.org/10.1056/NEJMoa1509388

76. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32-42. https://doi.org/10.1056/NEJMoa1215637

77. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-23. https://doi.org/10.1056/NEJMoa1400376

78. Cheson BD. Speed bumps on the road to a chemotherapy-free world for lymphoma patients. Blood. 2016;128:325-30. https://doi.org/10.1182/blood-2016-04-709477

Sažetak

BENDAMUSTIN:
STARI LIJEK U NOVOJ ERI ZA BOLESNIKE S NE-HODGKINOVIM LIMFOMIMA I KRONIČNOM LIMFOCITNOM LEUKEMIJOM

M. Bogeljić Patekar, V. Milunović, K. Mišura Jakobac, D. Perica, I. Mandac Rogulj, M. Kursar, A. Planinc-Peraica i S. Ostojić Kolonić

Cilj ovoga preglednog rada je procijeniti aktivnost bendamustina te njegovih kombinacija u ne-Hodgkinovim limfomima (NHL) i kroničnoj limfocitnoj leukemiji (KLL). Bendamustin je sada indiciran u Republici Hrvatskoj za liječenje rituximab-rezistentnog NHL-a i u bolesnika s KLL-om koji nisu kandidati za konvencionalnu terapiju. No, kombinacija bendamustina s rituximabom (B-R) u prvoj liniji terapije indolentnog NHL-a i limfoma plaštene zone pokazala se boljom od konvencionalne kemoterapije pa bi B-R trebao postati zlatni standard u prvoj liniji liječenja ovih limfoma. Protokol B-R također ima aktivnost u relapsnom indolentnom NHL-u te predstavlja opciju za bolesnike koji su progredirali nakon konvencionalne kemoterapije. U rituximab-rezistentnom NHL-u nedavna studija GADOLIN koja je proučavala dodatak obinutuzumaba bendamustinu pokazala je jasnu superiornost prema bendamustinu i promijenila zlatni standard u ovoj populaciji zahtjevnoj za liječenje. U KLL-u usprkos inferiornosti B-R prema FCR-u u studiji CLL10 B-R je bio obilježen boljim profilom toksičnosti te se može ponuditi pojedincima na temelju individualizirane odluke. U relapsnom okružju KLL-a dodatak ibrutiniba protokolu B-R pokazao je superiornost prema B-R s mogućom promjenom paradigme liječenja ovih bolesnika. Zaključno, bendamustin sam ili u kombinacijama pokazao je visoku aktivnost s povoljnim toksičnim profilom u liječenju indolentnih NHL-a i KLL bez mutacije del(17p).

Ključne riječi: Bendamustin hidroklorid; Alkilirajuća sredstva; Limfom, ne-Hodgkinov; Rituximab; Leukemija B-stanica, limfocitna; Obinutuzumab